eniluracil
Small moleculeexperimental
Clinical trial activity
13 trials · 14 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
8
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 1997 (NCT00001579)
Timeline
Indications
Mechanism of action
- Dihydropyrimidine dehydrogenaseINHIBITOR
DPYD inhibitor
5-Fluorouracil (5-FU) has a short half-life (8¿22 min) resulting from rapid metabolism in the liver and other tissues by the enzyme dihydropyrimidine dehydrogenase (DPD). Eniluracil is an experimental drug that is specifically designed to inactivate DPD and prolong the half-life of 5-FU. In clinical trials, eniluracil has been shown to increase the half-life of 5-FU by 8¿30-fold.
Chemistry & pharmacology
Loading structure…
SMILES
C#Cc1c[nH]c(=O)[nH]c1=O- Mol. weight
- 136.11 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL355200 ↗
Also known as
- 2,4(1h,3h)-pyrimidinedione, 5-ethynyl-
- 5-ethynyl-2,4(1h,3h)-pyrimidinedione
- 5-ethynyl-2,4(1h,3h)-pyrimidinedione
- 5-ethynyluracil
- 5-ethynyluracil
- 5-ethynyluracil
- 776c85
- 776c85
- 776c85
- adh300004
- compound 776c
- compound 776c
- compound 776c
- eniluracil
- eniluracil
- eniluracil
- eniluracil
- eniluracil
- ethynyluracil
- ethynyluracil
- gw776c85
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06568692 | Phase 2 | Oct 2, 2024 | Processa Pharmaceuticals |
| NCT04861987 | Phase 1 | Jun 18, 2021 | Processa Pharmaceuticals |
| NCT01231802 | Phase 2 | Apr 1, 2011 | Fennec Pharma |
| NCT00827580 | Phase 1 | Jan 1, 2009 | West Virginia University |
| NCT00319683 | Phase 1/Phase 2 (Phase 2) | Apr 27, 2006 | Fennec Pharma, Ward Veterans General Hospital, Taipei |
| NCT00264472 | Phase 1 | Jan 1, 2006 | Fennec Pharma, SCRI Development Innovations |
| NCT00264446 | Phase 1 | Dec 12, 2005 | Fennec Pharma, University of Alabama, Birmingham |
| NCT00004901 | Phase 1/Phase 2 (Phase 2) | Oct 1, 1999 | National Cancer Institute (NCI), Northwestern University, University of Chicago |
| NCT00005050 | Phase 1/Phase 2 (Phase 2) | Aug 1, 1999 | National Cancer Institute (NCI), New York University |
| NCT00003873 | Phase 3 | Apr 1, 1999 | Eastern Cooperative Oncology Group, National Cancer Institute (NCI) |
| NCT00004195 | Phase 2 | Sep 1, 1998 | Glaxo Wellcome, National Cancer Institute (NCI), University of Alabama, Birmingham |
| NCT00003254 | Phase 2 | Apr 1, 1998 | Albany Medical College, National Cancer Institute (NCI), Southwest Oncology Group |
| NCT00001579 | Phase 1 | Jun 1, 1997 | National Cancer Institute (NCI) |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (14)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 6 | 2 | 3 | 1997 |
| Fennec Pharma | For profit | 4 | 4 | 2 | 2005 |
| Processa Pharmaceuticals | For profit | 2 | 2 | 2 | 2021 |
| University of Alabama, Birmingham | Academic/Hospital | 2 | 1 | 2 | 1998 |
| Albany Medical College | Academic/Hospital | 1 | 0 | 1 | 1998 |
| Eastern Cooperative Oncology Group | Academic/Hospital | 1 | 0 | 1 | 1999 |
| Glaxo Wellcome | For profit | 1 | 0 | 1 | 1998 |
| New York University | Academic/Hospital | 1 | 1 | 1 | 1999 |
| Northwestern University | Academic/Hospital | 1 | 1 | 1 | 1999 |
| SCRI Development Innovations | For profit | 1 | 0 | 1 | 2006 |
| Southwest Oncology Group | Academic/Hospital | 1 | 1 | 1 | 1998 |
| University of Chicago | Academic/Hospital | 1 | 0 | 1 | 1999 |
| Ward Veterans General Hospital, Taipei | Academic/Hospital | 1 | 0 | 1 | 2006 |
| West Virginia University | Academic/Hospital | 1 | 1 | 1 | 2009 |
14 organizations
Page 1 / 1